EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity

Dao Thi Hong Le, Chuan Yang, Yue Zhang, Gui Zhao, Brandon Yi Loong Seow, Xinxin Zhao, Nithiyaa Balakrishnan, Ki Hyun Bae, James H P Hui, Yi Yan Yang

Journal of Controlled Release · 2026

DOI: 10.1016/j.jconrel.2026.115136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Dao Thi Hong Le und 9 weiteren Autor:innen. Beteiligte Einrichtung: Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, #06-01 Centros, Singapore 138668, Si…. Hauptthemen laut MEDLINE: Polyethylene Glycols, Nanoparticles, Polycarboxylate Cement, RNA, Messenger. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A*STAR Research Entities, National Research Foundation, Biomedical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA vaccines delivered by lipid nanoparticles (LNPs) have enabled clinical success in combating the COVID-19 pandemic, demonstrating LNPs as a promising nanocarrier for mRNA delivery. Despite this advance, use of PEGylated lipid (PEG-lipid) in LNPs has raised concerns about PEG-associated immunogenicity upon repeated dosing. Recent studies reported hydrophilic polymer lipids as replacement of PEG-lipid, which demonstrated the potential to reduce PEG-associated immune recognition. Most of these PEG-lipid alternatives are based on polymers with non-degradable polymer backbone. In this study, we synthesized a series of oligo(ethylene glycol)-functionalized polycarbonate lipids (OPL-1 to OPL-8) based on a polycarbonate backbone with reported biodegradability and biocompatibility to replace PEG-lipid such as ALC-0159 used in Comirnaty mRNA vaccine for attenuating PEG immunogenicity. Unlike ALC-0159 with 50 EG units existing in a linear form, oligo(ethylene glycol) (OEG) in OPLs is in a brush-like conformation. OEG length played a key role in formulating LNPs with desirable physicochemical properties. OPL-7 and OPL-8 with EG9 produced LNPs with nanosize, narrow size distribution, near-neutral surface charge and high encapsulation efficiency, comparable to ALC-0159 LNPs. OPL LNPs mediated significantly higher mRNA transfection efficiency in HEK293T and two model antigen-presenting cells (APCs) than ALC-0159 LNPs, which was associated with enhanced cellular uptake as evidenced by flow cytometry analysis. Endocytosis inhibition assay suggested that clathrin-mediated endocytosis was a major pathway for cellular uptake of LNPs, with caveolae-dependent endocytosis also contributing. A confocal microscopic study indicated comparable endosomal escape of OPL and ALC-0159 LNPs. In vivo and ex vivo bioimaging at 6 h post-administration demonstrated that OPL-7 and OPL-8 LNPs exhibited significantly reduced hepatic mRNA transfection and relatively higher lymph node mRNA transfection, resulting in significantly greater lymph node-to-liver mRNA transfection ratios. In a mouse vaccination study, OPL-7 and OPL-8 LNPs loaded with mRNA encoding the spike glycoprotein of SARS-CoV-2 Delta variant elicited robust humoral immune responses without causing significant toxicity. Repeated dosing of OPL-7 or OPL-8 LNPs induced significantly lower anti-PEG IgM response than ALC-0159 LNPs. Moreover, OPL-7 or OPL-8 avoided recognition by pre-existing anti-PEG antibodies. Collectively, these findings identify OPL-7 and OPL-8 as promising PEG-lipid alternatives for mRNA delivery that maintain delivery performance while attenuating anti-PEG antibody responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsNanoparticlesPolycarboxylate CementRNA, MessengerLipidsCOVID-19 VaccinesAnimalsFemaleMiceHumansCOVID-19mRNA VaccinesLiposomes

Stichwörter der Autor:innen

Lipid nanoparticlesOligo(ethylene glycol)PEG immunogenicity mitigationPolycarbonatemRNA delivery

Substanzen

Polyethylene GlycolsPolycarboxylate CementpolycarbonateRNA, MessengerLipidsLipid NanoparticlesCOVID-19 VaccinesmRNA VaccinesLiposomes

Autor:innen und Institutionen

  • Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, #06-01 Centros, Singapore 138668, Singapore; Department of Orthopaedic Surgery, Yong Loo Lin School of Med…
  • Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, #06-01 Centros, Singapore 138668, Singapore.
  • Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore 119288, Singapore.

Förderung

  • A*STAR Research Entities
  • National Research Foundation
  • Biomedical Research Council

Zitieren

APA

Le, D. T. H., Yang, C., Zhang, Y., Zhao, G., Seow, B. Y. L., Zhao, X., Balakrishnan, N., Bae, K. H., Hui, J. H. P., & Yang, Y. Y. (2026). Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115136

Vancouver

Le DTH, Yang C, Zhang Y, Zhao G, Seow BYL, Zhao X, et al. Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115136

BibTeX
@article{Le2026,
  author = {Le, Dao Thi Hong and Yang, Chuan and Zhang, Yue and Zhao, Gui and Seow, Brandon Yi Loong and Zhao, Xinxin and Balakrishnan, Nithiyaa and Bae, Ki Hyun and Hui, James H P and Yang, Yi Yan},
  title = {Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity},
  journal = {Journal of Controlled Release},
  year = {2026},
  doi = {10.1016/j.jconrel.2026.115136}
}
Kostenlos starten →